Sirion Partners with IBM to Accelerate Enterprise Contract Management with AI-Powered Contract Lifecycle Management
Sirion, a leader in AI-powered contract lifecycle management (CLM), today announced a collaboration to embed IBM watsonx to redefine CLM for enterprises. As the first adopter of this combined offering, IBM will also deploy Sirion CLM to help streamline its own order-to-cash (O2C) and source-to-pay (S2P) processes.
Sirion’s Generative AI, embedded with IBM watsonx, is designed to make contracting accessible to everyone in an enterprise while empowering them to mine insights from across contracts, enterprise data, and other data resources. This can enable customers to establish causal connections between business processes and outcomes, unlocking new avenues of growth.
watsonx is IBM’s AI and data platform, designed to help enterprises scale and accelerate the impact of AI adoption to deliver enterprise value through an open and trusted environment. The technology is built with governance that allows customers to create responsible and explainable AI, data and workflows; supports regulatory compliance efforts; and offers visibility to help gauge fairness and transparency.
“We are excited to collaborate with Sirion to accelerate the future of AI-powered enterprise contract management and by their choice to embed watsonx as the backbone,” said Joanne Wright, SVP of Transformation and Operations, IBM. “Sirion’s platform offers a common data model across our core business applications like S/4 HANA, SAP Ariba and Salesforce, and can help operate as middleware by creating a shared data language simplifying IBM's order to cash and source-to-pay processes."
Using Sirion, IBM will be able to establish a common vein of risk and business intelligence that runs across the enterprise, enabling legal, sales, procurement, and finance operations to consume contract intelligence as a service that fuels strategic decisions with global impact.
“By embedding watsonx, Sirion's category-leading AI helps our clients transition their contracts from static documents to dynamic assets at the heart of business strategy. With watsonx embedded inside Sirion, enterprises will now be able to tap into multiple foundation models where they can train and fine-tune these models using their own data,” said Sirion's Founder and CEO, Ajay Agrawal.
With Sirion and IBM collaborating, clients will benefit from the emerging Generative AI contracting experience poised to redefine the contract management landscape for enterprises.
About Sirion:
Bringing together category-leading innovation, unrivaled Contract Lifecycle Management expertise, and a deep commitment to customer success, Sirion helps the world’s leading businesses contract smarter. Powered by intelligence uniquely connected across the complete contract lifecycle, Sirion’s easy-to-use, highly configurable Smarter Contracting platform brings legal, procurement, sales, and business teams together to author stronger contracts, improve risk management, and strengthen counterparty relationships. Sirion is trusted by over 200 of the world’s most successful organizations to manage 5 million+ contracts worth more than $450 billion across 70+ countries. For more information, visit www.sirion.ai.
About IBM:
IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. More than 4,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM's long-standing commitment to trust, transparency, responsibility, inclusivity and service.
Visit www.ibm.com for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231017009994/en/
Contact information
Media Contact:
Olivia Farber
(949) 542-9232
media.relations@sirionlabs.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Sustainable Forestry Coalition Welcomes New Member, Suzano6.12.2023 11:37:00 CET | Press release
In September a group of leading global sustainable forestry companies launched the International Sustainable Forestry Coalition (ISFC), to enable the sector to positively contribute to global policy processes focused on the transition from a fossil-based economy to a circular bioeconomy. Today the ISFC is delighted to announce that Suzano, one of the world’s major forestry sector companies, has become a member. Suzano, headquartered in Brazil, is a globally respected forestry sector leader. With almost a hundred years in operation, the company manages extensive sustainable timber plantation estates and forest conservation areas, and creates a vast range of fibre-based products. One out of every three tissue products used in the world today will have come from Suzano’s operations. Convening Chair of the ISFC Dr. David Brand said, “With the inclusion of Suzano in the ISFC, the group represents more than 12.6 million hectares (31 million acres) of forests for conservation and production i
Forrester: European Retail Sales To Reach €2.7 Trillion By 20286.12.2023 11:00:00 CET | Press release
Forrester (Nasdaq: FORR) forecasts that total retail sales of Europe-5 countries (France, Germany, Italy, Spain, and the UK) will increase from €2.3 trillion in 2023 to reach €2.7 trillion in 2028 at a 2.9% compound annual growth rate (CAGR). Forrester’s recently released report, Europe-5 Online Retail Forecast, 2023 To 2028, estimates total retail sales, online retail sales, and online retail penetration across 22 product categories, including fashion, homeware, food and drink, consumer electronics, and media, for each of the Europe-5 economies. Germany holds the largest share of the retail market among these five countries, followed (in order) by the UK and France. In 2022, offline retail growth outpaced online retail growth for the first time as more consumers shopped in stores, and this momentum continued into 2023, but the fundamental growth drivers of online retail such as greater product selection, round-the-clock availability, and competitive pricing remain strong. As a result,
Kaneka Acquires Japan Medical Device Technology6.12.2023 10:40:00 CET | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has acquired all shares of Japan Medical Device Technology Co., Ltd. (Headquarters: Kamimashiki-gun, Kumamoto; President: Shuzo Yamashita) (hereinafter JMDT), a developer and manufacturer of medical devices, on November 30, 2023, and made it a wholly owned subsidiary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206372197/en/ Stent before expansion (Photo: Business Wire) Kaneka manufactures and sells endovascular catheters, which are devices used in the treatment of cardiac, peripheral vascular, and cerebrovascular diseases. In particular, stenting*1 for the treatment of coronary artery diseases such as atherosclerosis has a market worth 30 billion yen in Japan, and Kaneka is aiming to expand its business in this area. JMDT has high technological capabilities in the research and development of coronary stents and is one of the lead
CommBox launches Era AI to enable customer service to be intelligently automated and CX costs to be cut by 40%6.12.2023 10:00:00 CET | Press release
Today CommBox, the pioneer in AI-powered customer communications, is launching its new generative AI solution. Designed for medium to large businesses across a range of industries including healthcare, banking, retail, telecommunications and insurance, Era AI is based on a winning combination of both proprietary technology developed by CommBox and commercial large language models. Era AI’s functionality scans enterprise knowledge sources and, in just seconds, provides customers with accurate, highly personalised information through the digital messaging channel of their choice. Era AI delivers customer service automation, reduces costs for organisations, and dramatically increases the speed and accuracy of enquiry handling. It does this all while increasing customer satisfaction, with CommBox customers seeing a 92% customer satisfaction rate on average. Central to this is Era AI’s ability to analyse a brand’s entire resource base, such as support articles, help and knowledge centres, a
New Post Hoc Phase 3 Data Analysis Shows AJOVY ® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity6.12.2023 08:00:00 CET | Press release
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announces that a post hoc analysis4 of two phase 3 clinical studies presented today at the European Headache Congress has shown the effectiveness of the migraine prevention treatment AJOVY®(fremanezumab) in reducing migraine attacks in patients with migraine and co-morbid obesity. Migraine and obesity are both associated with high levels of disability3 and both conditions are more prevalent amongst females5,6. It is estimated that 59% of people in Europe are either overweight or obese, with almost a quarter (23%) of adults living with obesity5. A higher body mass index (BMI) is frequently associated with increased migraine prevalence and severity, and an increased number of adverse effects3. As such, assessing the efficacy and safety of migraine preventative treatment in patients with obesity can help guide migraine management and treatment decisions. The post hoc analysis of the HALO-LTS1 and FOCUS2 phase 3 studies compared the